Employees
50
Industry
Research and Development in Biotechnology
kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
September 13, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Insights
September 05, 2023 | 5:34 pm
Portfolio Pulse from Benzinga Insights
August 04, 2023 | 10:08 am
Portfolio Pulse from Benzinga Insights
July 28, 2023 | 4:36 pm
Portfolio Pulse from Lisa Levin
June 30, 2023 | 4:34 pm
Portfolio Pulse from Benzinga Insights
June 30, 2023 | 1:12 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2023 | 8:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2023 | 4:53 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.